Tests REGN5678 alone or with cemiplimab in advanced prostate cancer and other tumors
Tests REGN5678 with or without cemiplimab in adults with advanced prostate cancer.
Key facts
- Who runs it
- Regeneron Pharmaceuticals
- Where
- Boston, Charlottesville, Columbus, Denver, Detroit, Gilbert, Houston, Jacksonville, Morgantown, New Haven, New York, Philadelphia, Phoenix, Portland, Providence, Rochester, Santa Monica, Tampa, and Tucson, United StatesSee the 24 sitesAlso in 1 other country, 3 sites
- Trial code
- Registry title
- A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 345 people, planned
- Started
- 12 Aug 2019
- Expected to end
- 15 Nov 2027
- Type of study
- Interventional, 4 groups
- Treatments tested
- REGN5678
- Cemiplimab
- Record updated
- 4 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with metastatic castration-resistant prostate cancer (men) or metastatic clear cell kidney cancer (men and women), whose cancer has gotten worse after earlier treatments.
- Age
- 18 years or older
- Sex
- Men for the prostate cancer groups. Men and women for the kidney cancer groups.
- Disease stage
- Prostate cancer: adenocarcinoma without pure small cell carcinoma, with PSA of 4 ng/mL or more that has risen within the last 6 months. Kidney cancer: metastatic clear cell renal cell carcinoma with at least one measurable lesion.
- Earlier treatment
- Prostate cancer: at least 2 earlier lines of treatment, including a second-generation anti-androgen drug and 177Lu-PSMA-617 or another lutetium-based PSMA-targeted radioligand. Kidney cancer: cancer got worse after at least 1 earlier line of treatment, including an anti-PD-1/PD-L1 therapy and ipilimumab and/or a tyrosine kinase inhibitor.
- Biomarker or test result
- PSA of 4 ng/mL or more at screening (prostate cancer groups).
Main reasons for not taking part
- Approved systemic therapy within 3 weeks of dosing, or not yet recovered from its side effects
- Earlier PSMA-targeting therapy, other than a PSMA-targeting radioligand in prostate cancer
- Needing ongoing steroid treatment above 10 mg prednisone per day within the last week
- Significant autoimmune disease treated with immune-suppressing drugs within the last 5 years
- Uncontrolled HIV, hepatitis B or hepatitis C infection, or an immunodeficiency diagnosis
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- mCRPC cohorts (men):
- Men with histologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma
- PSA value at screening ≥4 ng/mL that has progressed within 6 months prior to screening as defined in the protocol
- Has received ≥2 lines prior systemic therapy approved in the metastatic and/or castration-resistant setting (in addition to Androgen Deprivation Therapy [ADT]) including at least:; one second-generation anti-androgen therapy (eg, abiraterone, enzalutamide, apalutamide, or darolutamide); 177Lu-PSMA-617 radiotherapy, or another lutetium-based PSMA targeted radioligand, as described in the protocol; ccRCC cohorts (men and women):
- Histologically or cytologically confirmed RCC with a clear-cell component
- Diagnosis of metastatic ccRCC with at least one measurable lesion via RECIST 1.1 criteria
- Has progressed on or after ≥1 line prior systemic therapy approved in the metastatic setting. Prior treatment must include an anti-Programmed Death-1 (receptor) [PD-1]/Programmed Death-Ligand 1 (PD-L1) therapy and either ipilimumab and/or a tyrosine kinase inhibitor
Who cannot take part
- Has received treatment with an approved systemic therapy within 3 weeks of dosing or has not yet recovered (ie, grade ≤1 or baseline) from any acute toxicities, as described in the protocol
- Has received any previous systemic biologic therapy within 5 half-lives of first dose of study therapy, as described in the protocol
- Has received prior PSMA-targeting therapy with the exception of a PSMA targeting radioligand (eg. 177Lu-PSMA-617) in mCRPC
- Dose Escalation: Has had prior anti-cancer immunotherapy (other than sipuleucel-T) within 5 half-lives prior to study therapy
- Dose Expansion (mCRPC only): Has had prior anti-cancer immunotherapy, as described in the protocol
- Any condition that requires ongoing/continuous corticosteroid therapy (>10 mg prednisone/day or anti-inflammatory equivalent) within 1 week prior to the first dose of study therapy
- Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, as described in the protocol
- Encephalitis, meningitis, neurodegenerative disease (with the exception of mild dementia that does not interfere with Activities of Daily Living [ADLs]) or uncontrolled seizures in the year prior to first dose of study therapy
- Uncontrolled infection with Human Immunodeficiency Virus (HIV), hepatitis B or hepatitis C infection; or diagnosis of immunodeficiency; NOTE: Other protocol defined Inclusion/Exclusion Criteria apply
Where in United States
Also in 1 other country, 3 sites
- Massachusetts General HospitalBoston, United StatesContact: Clinical Trials AdministratorTaking people
- Emily Couric Clinical Cancer CenterCharlottesville, United StatesContact: Clinical Trials AdministratorTaking people
- James Cancer Hospital and Solove Research InstituteColumbus, United StatesContact: Clinical Trials AdministratorTaking people
- Sarah Cannon Research Institute (SCRI)Denver, United StatesContact: Clinical Trials AdministratorTaking people
- Henry Ford HealthDetroit, United StatesContact: Clinical Trials AdministratorTaking people
- Banner MD Anderson Cancer CenterGilbert, United StatesContact: Clinical Trials AdministratorTaking people
- MD Anderson Cancer CenterHouston, United StatesContact: Clinical Trials AdministratorTaking people
- Mayo Clinic- JacksonvilleJacksonville, United StatesContact: Clinical Trials AdministratorTaking people
- West Virginia UniversityMorgantown, United StatesContact: Clinical Trials AdministratorTaking people
- Yale University HospitalNew Haven, United StatesContact: Clinical Trials AdministratorTaking people
- Columbia University - The Trustees of Columbia University in the City of New YorkNew York, United StatesContact: Clinical Trials AdministratorTaking people
- Icahn School of Medicine at Mount SinaiNew York, United StatesContact: Clinical Trials AdministratorTaking people
- Montefiore Medical CenterNew York, United StatesContact: Clinical Trials AdministratorTaking people
- NYU Langone Health Perlmutter Cancer CenterNew York, United StatesContact: Clinical Trials AdministratorTaking people
- Thomas Jefferson University HospitalPhiladelphia, United StatesContact: Clinical Trials AdministratorTaking people
- Mayo ClinicPhoenix, United StatesContact: Clinical Trials AdministratorTaking people
- Oregon Health & Science University (3485 S. Bond)Portland, United StatesContact: Clinical Trials AdministratorTaking people
- Providence Portland Medical CenterPortland, United StatesContact: Clinical Trials AdministratorNo longer taking part
- Lifespan Cancer InstituteProvidence, United StatesContact: Clinical Trials AdministratorTaking people
- Mayo ClinicRochester, United StatesContact: Clinical Trials AdministratorTaking people
- University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center) - RochesterRochester, United StatesContact: Clinical Trials AdministratorTaking people
- John Wayne Cancer Institute (JWCI)Santa Monica, United StatesContact: Clinical Trials AdministratorTaking people
- Moffitt Cancer Center - McKinley DriveTampa, United StatesContact: Clinical Trials AdministratorTaking people
- University of ArizonaTucson, United StatesContact: Clinical Trials AdministratorTaking people
About the trial
What the trial wants to find out
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug[s]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab.
Read full original descriptionShow less
The study has 2 parts. The goal of Part 1 (dose escalation) is to determine a safe dose(s) of REGN5678 when it is given alone or in combination with cemiplimab. The goal of Part 2 (dose expansion) is to use the REGN5678 drug dose(s) found in Part 1 to see how well REGN5678 alone or in combination with cemiplimab works to shrink tumors.
This study is looking at several other research questions, including:
1. Side effects that may be experienced by taking REGN5678 alone or in combination with cemiplimab 2. How REGN5678 alone or in combination with cemiplimab works in the body 3. How much REGN5678 and/or cemiplimab are present in the blood 4. To see if REGN5678 alone or in combination with cemiplimab works to reduce the size of the tumor by helping the immune system destroy the tumor
The 4 groups in the trial
- mCRPC - dose escalation cohortTreatment being tested
REGN5678 with or without cemiplimab
Treatment: REGN5678 and Cemiplimab
- mCRPC - dose expansion cohortTreatment being tested
REGN5678 with or without cemiplimab
Treatment: REGN5678
- ccRCC - dose escalation cohortTreatment being tested
REGN5678 with or without cemiplimab
Treatment: REGN5678 and Cemiplimab
- ccRCC - dose expansion cohortTreatment being tested
REGN5678 with or without cemiplimab
Treatment: REGN5678
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression
- Plain-language title
- Tests REGN5678 alone or with cemiplimab in advanced prostate cancer and other tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 4 November 2026